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ABSTRACT
Expression of cytochrome P450-1A1 (CYP1A1) is suppressed under physiologic conditions but 
is induced (a) by polycyclic aromatic hydrocarbons (PAHs)which can be metabolized by 
CYP1A1 to carcinogens, and (b) in majority of breast cancers. Hence, phytochemicals or dietary 
flavonoids, if identified as CYP1A1 inhibitors, may help in preventing PAH-mediated 
carcinogenesis and breast cancer. Herein, we have investigated the cancer chemopreventive 
potential of a flavonoid-rich Indian medicinal plant, Pongamia pinnata (L.) Pierre. Methanolic 
extract of its seeds inhibits CYP1A1 in CYP1A1-overexpressing normal human HEK293 cells, 
with IC50 of 0.6 µg/mL. Its secondary metabolites, the furanoflavonoids pongapin/ lanceolatin B, 
inhibit CYP1A1 with IC50 of 20 nM. Although the furanochalcone pongamol inhibits CYP1A1 
with IC50 of only 4.4 µM, a semisynthetic pyrazole-derivative P5b, has ~10-fold improved 
potency (IC50, 0.49 M). Pongapin/ lanceolatin B and the methanolic extract of P. pinnata seeds 
protect CYP1A1-overexpressing HEK293 cells from B[a]P-mediated toxicity. Remarkably, they 
also block the cell cycle of CYP1A1-overexpressing MCF-7 breast cancer cells, at the G0-G1 
phase, repress cyclin D1 levels and induce cellular-senescence. Molecular modeling studies 
demonstrate the interaction pattern of pongapin/lanceolatin B with CYP1A1. The results strongly 
indicate the potential of methanolic seed-extract and pongapin/lanceolatin B for further 
development as cancer chemopreventive agents. 
KEYWORDS: Furanoflavones; Pongapin; Lanceolatin B; Cell Cycle; Senescence; 
CYP1A1
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1. INTRODUCTION
The polycyclic aromatic hydrocarbons (PAHs) belong to a ubiquitous group of environmental 
procarcinogens, which have two or more fused aromatic (benzene) rings. The PAHs are 
generated primarily from coal tar, tobacco smoke, wood burning and grilled meats.1 The low-
molecular-weight PAHs (which contain 2-3 rings) occur in the atmosphere predominantly in the 
vapor phase, whereas multi-ringed PAHs (which contain 5 rings or more) are largely bound to 
environment-borne fine particles. In particular, the particle-bound PAHs are considered to be 
highly hazardous to human health. One of the most common particle-bound PAH is 
benzo[a]pyrene (B[a]P). Concentrations of B[a]P in human plasma is often used as a marker for 
exposure to carcinogenic PAHs, as the contribution of B[a]P to the total carcinogenic potential 
has been reported to be very high.2 On human exposure, B[a]P undergoes metabolic activation 
by cytochrome P450-1A1 (CYP1A1) enzyme which is an extrahepatic phase I metabolizing 
enzyme that is suppressed under physiologic conditions. CYP1A1 is induced, via the aromatic 
hydrocarbon receptor (AhR), by PAHs which act as ligands of AhR.3-6 The procarcinogen B[a]P, 
which also induces CYP1A1 expression via AhR, is metabolized by CYP1A1 to carcinogenic 
benzo[a]pyren-7,8-dihydrodiol-9,10-epoxide7, 8 which is mutagenic, highly carcinogenic and is 
listed as a group 1 carcinogen by the International Agency for Research on Cancer (IARC).7, 9 
The role of human CYP enzymes in procarcinogen metabolism has been studied extensively10 
and it is the CYP1A1 enzyme that primarily plays a major part in B[a]P activation.7, 10, 11 
Therefore, inhibitors of CYP1A1 have extensively been investigated with the goal of discovering 
chemical agents that would prevent cancer12, 13 by overcoming PAH-mediated carcinogenicity.14-
21
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Although CYP1A1 is practically non-existent in normal breast tissues, its levels are relatively 
high, depending on the grade of the tumor, in majority of breast cancer tumors.22, 23 Because of 
CYP1A1’s pervasive expression in breast cancer; there is interest in modulating CYP1A1 
activity for breast cancer therapeutics.24-27 Small interfering RNA (siRNA) molecules have been 
used to investigate the consequence of knocking down CYP1A1 mRNA levels. It was seen that 
CYP1A1-expressing breast cancer cells arrest at G0-G1 phase of the cell cycle and are associated 
with reduction of cyclin D1 and increased apoptosis.28 Interestingly, inhibition of proliferation 
was not at all affected by α-naphthoflavone (ANF).29 Although ANF is a known CYP1A1 
microsomal enzyme inhibitor, it is highly insoluble and does not inhibit CYP1A1 enzyme within 
live cells.19, 21, 30 
Pongamia pinnata (L.) Pierre (Family: Fabaceae) is an Indian beech tree which has been 
reported to possess many medicinal properties.31-44 Pongamol, the major constituent of this plant, 
is also reported as an antiproliferative45 and an antihyperglycemic agent.46 Since karanjin and 
pongamol, the chemical constituents of Pongamia pinnata, induce NQO1 [NAD(P)H quinine 
oxidoreductase 1] they have been reported as cancer chemopreventive agents 47. Recently we 
reported karanjin as a potent CYP1 inhibitor which could act to protect cells from undergoing 
carcinogenesis.48 However, the CYP1A1 inhibitory potential of P. pinnata (L.) Pierre extracts or 
its other constituents have never been explored. The seeds of this tree are reported to contain 
many flavonoids. Therefore, the present study was primarily aimed to investigate the potential of 
Pongamia pinnata seed extracts and its chemical constituents to inhibit CYP1A1 using (a) 
Sacchrosomes™ (i.e. microsomal enzymes which areisolated from whole yeast cells) and (b) live 
normal human kidney cells HEK293, grown in suspension, which overexpress CYP1A1 
protein.20, 48, 49 The selectivity of the potent CYP1A1 inhibitors, over other CYP1, CYP2 and 
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CYP3 sub-family of enzymes, was determined. The most potent inhibitors isolated from P. 
pinnata, of CYP1A1 (i.e. the furanoflavones50 pongapin and lanceolatin B) and the methanolic 
seed extract of P. pinnata were further studied to see if they would overcome B[a]P mediated 
toxicity in CYP1A1-overexpressing normal human HEK293 cells.20, 48, 49 Furthermore, pongapin 
and lanceolatin B were used to examine if they would inhibit recombinant human breast cancer 
MCF-7 cells that overexpress CYP1A1 (referred to as MCF7-1A1 cells). 
2. RESULTS AND DISCUSSION
2.1. Furanoflavones from Pongamia pinnata Potently Inhibit CYP1A1 and CYP1B1. The 
methanolic extract (ME) of Pongamia pinnata seeds showed potent inhibition of CYP1A1 and 
CYP1B1 in Sacchrosomes™ as well as in live HEK293-CYP1A1 cellular assay. The IC50 values 
for inhibition of CYP1A1 and CYP1B1 in live cells were 0.6 and 0.4 g/mL, respectively (Table 
S1, supporting information). The interesting CYP1 (i.e. CYP1A1 and CYP1B1) inhibitory 
activity of extracts indicated that further phytochemical investigation of methanolic extract may 
provide an opportunity to discover new potent CYP1 inhibitors.
The ME was partitioned with different organic solvents viz. hexane, ethyl acetate, chloroform 
and n-butanol. Repeated column chromatography of ethyl acetate fraction led to the isolation of 
five compounds, which were characterized by comparison of their spectral data with literature 
values. The isolated compounds include karanjin, pongamol, pongapin, ovalitenone, and pongol. 
The two furanoflavoneslanceolatin B and pongaglabrone which naturally occur in seeds of this 
tree, were synthesized from furano-hydroxychalcones pongamol and ovalitenone by treatment 
with potassium carbonate in DMF.51
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All isolated natural products karanjin, pongol, pongapin, pongamol and ovalitenone along 
with synthesized natural products lanceolatin B and pongaglabrone were first tested for inhibition 
of CYP1A1 and CYP1B1 in Sacchrosomes™, baker’s yeast derived isolated microsomal 
enzymes (Table 1). Amongst the 7 compounds, pongapin, ovalitenone, pongol, and lanceolatin B 
displayed potent inhibition of CYP1A1 with IC50 values in the range of 71-690 nM. The most 
potent CYP1A1 inhibitors were the furanoflavones, pongapin and lanceolatin B, showing IC50 
values of 71 and 76 nM, respectively. Next, all the 7 compounds were tested for inhibition of 
CYP1A1 and CYP1B1 enzymes expressed within live HEK293 cells. Karanjin displayed potent 
inhibition of CYP1A1 as well as CYP1B1,expressed within HEK293 cells, with IC50 values of 
0.03 and 0.22 M, respectively.48 Furanoflavones, pongapin and lanceolatin B, displayed potent 
inhibition of CYP1A1, with the same IC50 value of 20 nM in the live HEK293 cellular assay. As 
CYP1A1 inhibitors, pongapin and lanceolatin B had 53 and 19.5-fold specificity vis-à-vis the 
CYP1B1 enzyme in live HEK293 cells, that individually expressed the two enzymes (Table 1). 
We have found that the true potential of a chemical compound or a natural product to inhibit a 
CYP enzyme can be determined ideally using CYP enzyme activities expressed within live 
human HEK293 cells rather than with CYP enzymes bound to endoplasmic reticular membranes 
which are isolated from recombinant cells, and which are referred to as microsomal enzymes 
(commercially available as Sacchrosomes™, Baculosomes™, Bactsosomes™ or Supersomes™). 
Our findings areanalogous to the fact that human hepatocytes are generally preferred to 
microsomal enzymes by the pharmaceutical industry for IC50 and drug metabolism studies and 
would have widely been used if they were more readily available for routine use.52 Using US 
Food and Drug Administration (FDA)-approved CYP inhibitors, we have seen that IC50 values 
for inhibition of CYPs expressed in HEK293 cells are very similar to that obtained using human 
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hepatocytes, and often have stark differences to IC50 values obtained using microsomal enzymes 
(manuscript in preparation).
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Figure 1. The structures of Pongamia pinnata constituents isolated or semi-synthetically prepared. 
Karanjin, pongol, pongapin, pongamol and ovalitenone were isolated from Pongamia pinnata. 
Lanceolatin and pongaglabrone were synthesized from pongamol and ovalitenone, respectively.
Table 1. In vitro CYP1A1 and CYP1B1 inhibitory activity of isolated constituents of P. pinnata in live 
human HEK293 cells, grown in suspension, that bear the human CYP1A1/CYP1B1 genes and which 
overexpress the CYP1A1/CYP1B1enzymes. a
IC50 (µM) ± SD (Sacchrosomes™)
IC50 (µM) ± SD 
(HEK293)
Entry
CYP1A1 CYP1B1 CYP1A1 CYP1B1
Karanjin 2.7 ± 0.5 4.1 ± 0.6 0.03 ± 0.008 0.03 ± 0.008
Pongamol 2.4 ± 0.5 3.9 ± 0.7 4.4 ± 0.9 4.5 ± 0.8
Pongapin 0.071 ± 0.008 0.95 ± 0.12 0.02 ± 0.005 1.06 ± 0.06
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Ovalitenone 0.28 ± 0.07 0.6 ± 0.5 0.48 ± 0.15 1.5 ± 0.6
Pongol 0.69 ± 0.11 3.8 ± 0.8 0.24 ± 0.11 1.2 ± 0.2
Lanceolatin B 0.076 ± 0.008 0.29 ± 0.07 0.02 ± 0.005 0.39 ± 0.12
Pongaglabrone 8.2 ± 1.2 3.4 ± 0.7 6.4 ± 0.9 6.8 ± 1.1
ANFb 0.05 ± 0.02 0.04 ± 0.02 >10 >10
aAll values represent mean and standard deviations (± SD) from three independent experiments. b ANF 
(alpha-naphthoflavone) is a positive control used in this experiment.
2.2. Semisynthetic Modification of the Furanochalcone, Pongamol, a Major Constituent 
of Pongamia pinnata, Results in Improved CYP1A1 inhibition. Pongamol is the major 
bioactive constituent of this plant;53 therefore, it was isolated in gram quantities. Chemically, 
pongamol has a keto-enol functionality which provides an interesting handle for synthetic 
modifications. As described earlier, by base-mediated ring cyclization we could convert 
pongamol to the furanoflavone, lanceolatin B.51 Further, we were interested in cyclizing this 
keto-enol functionality in the form of a heterocycle. Pongamol exists in keto-enol tautomeric 
forms (β-keto dihydrochalcone and β-hydroxychalcone).54 Treatment of pongamol with 
hydroxylamine hydrochloride, in the presence of acetic acid, resulted in formation of oxazole 
derivatives P1a and P1b in combined yields of 60%. Pair of regioisomers were formed in each 
reaction because of the presence of pongamol in two states, as β-keto dihydrochalcone and as β-
hydroxychalcone. When pongamol was treated with different substituted phenyl hydrazines, a 
series of regioisomeric pairs of pyrazole derivatives P2a-P7a and P2b-P7b were obtained in 52-
73% yield (Figure 2A). All pairs of regioisomers were separated from each other, using semi-
preparative HPLC. All compounds were characterized by NMR and MS analysis.
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The 1H NMR spectrum of the mixture of a representative regioisomeric pair P7a and P7b 
clearly showed the presence of two singlets at  3.70 and 4.11 ppm, indicating the presence of 
two methoxy groups, one each for a regioisomer. Similarly, the 13C NMR spectrum showed two 
distinct peaks at  59.8 (OMe) and 60.5 ppm (OMe). It is interesting to mention that the pair of 
regioisomers showed a uniform pattern of HPLC retention times and chemical shift values for 
OMe groups in the pair of isomers. Thus, these findings can be generalized for this class of 
compounds. The HPLC retention times and OMe signals in the NMR spectra of these pairs of 
regioisomers are summarized in Figure 2B. In all cases, one particular isomer is eluted faster 
than the other from the HPLC column. Similarly, the methoxy signal of 2′-phenyl isomers is 
downfield shifted in both 1H and 13C NMR in comparison to the methoxy signal of 1′-phenyl 
isomers. The final confirmation and assignment of the regioisomers was done by recording 
single crystal X- ray crystal structure of one representative pair P7a/P7b. The ORTEP (Oak 
Ridge Thermal Ellipsoid Plot Program) diagrams of these isomers are shown in Figure 2C. 
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Entry tR (min) 
in HPLC
1H NMR
(OCH3) ppm
13C NMR
(OCH3) ppm
P2a/P2b 7.74/8.78 3.68/4.10 59.2/60.5
P3a/P3b 6.34/6.60 3.85/4.11 59.8/60.5
P4a/P4b 5.73/6.22 3.71/4.12 59.4/60.5
P5a/P5b 4.24/4.80 3.67/4.11 60.4/60.5
P6a/P6b 7.33/8.26 3.68/4.01 59.3/60.4
P7a/P7b 7.17/7.19 3.87/4.10 59.6/59.7
A.
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Figure 2. (A). Synthesis of pongamol derivatives P1a-P7a, P1b-P7b. Reagents and conditions: (a) 
CH3COOH, 70 oC, 4 h, 52-73%. (B). Parameters (HPLC retention time and NMR chemical shift values) to 
distinguish a pair of regioisomers. (C) ORTEP diagram of regioisomerP7a and P7b.
All synthesized derivatives were tested for inhibition of CYP1A1/ CYP1B1 in 
Sacchrosomes™ at 10 μM concentration. Among all the derivatives tested, the compounds P4b, 
P5a and P5b showed promising inhibition (>70%) of CYP1A1 in Sacchrosomes™. However, 
none of the compounds was much effective against CYP1B1. Furthermore, out of the two 
positional isomers, particularly the one isomer e.g. P4a versus P4b – the isomer ‘b’ is more 
active than ‘a’. A similar trend was observed among all pairs (Table 2). The compounds P4b, 
P5a and P5b also showed potent inhibition of CYP1A1 in live recombinant human HEK293 
cells (>84% inhibition at 10 µM).
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Table 2. In vitro CYP1A1 and CYP1B1 inhibitory activity of pongamol derivatives in Sacchrosomes™ 
(yeast derived microsomal enzymes), at 10 M concentration. 
% inhibition at 10 μM (SacchrosomesTM)a
CYP1A1 CYP1B1Regio-
isomeric 
pair
O OMe
N N
R
P2a-P7a
O OMe
N N
R
P2b-P7b
O OMe
N N
R
P2a-P7a
O OMe
N N
R
P2b-P7b
P1a/P1bb 36.1 ± 2.4 48.9 ± 1.6 2.3 ± 2.2 0.6 ± 0.1
P2a/P2b 27.9 ± 4.2 49.5 ± 3.2 1.1 ± 0.6 20.7 ± 0.9
P3a/P3b 30.6 ± 1.5 68.3 ± 2.7 0.7 ± 0.3 0 ± 0.03
P4a/P4b 31.6 ± 1.9 88.8 ± 2.4 3.9 ± 2.8 46 ± 1.5
P5a/P5b 85.7 ± 4.2 95.4 ± 3.5 67.8 ± 2.2 28.1 ± 2.3
P6a/P6b 9.7 ± 0.3 47.4 ± 2.8 2.3 ± 0.3 16.8 ± 1.2
P7a/P7b 28.6 ± 4.3 53.7 ± 5.1 2.2 ± 1.2 3.3 ± 0.6
ANFc 97 ± 3.5 98 ± 2.2
aAll values represent mean and standard deviations (± SD) from three independent experiments. b the 
regioisomeric pair P1a/ P1b contains "3-(4-methoxybenzofuran-5-yl)-5-phenylisoxazole" as P1a whereas 
"5-(4-methoxybenzofuran-5-yl)-3-phenylisoxazole" as P1b. The structures of this pair are shown in 
Figure 2. cANF (alpha-naphthoflavone) is a positive control used in this experiment.
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Next, for determination of IC50 for inhibition of CYP1A1 and CYP1B1 enzymes, the best pair 
P5a/ P5b, was chosen as a representative example (Table 3). The isomers P5a and P5b inhibited 
CYP1A1 enzyme in live HEK293 cell assays, with IC50 values of 8.6 and 0.49 µM, respectively. 
The results indicate that the derivative P5b possesses 10-fold higher CYP1A1 inhibitory activity 
than its parent natural product pongamol (IC50, 4.4 µM).
Table 3. IC50 values for inhibition of CYP1A1 and CYP1B1 for selected regioisomeric pairsusing 
Sacchrosomes™ and CYP-expressing live HEK293 cells. 
IC50 (µM) ± SD (SacchrosomesTM)a IC50 (µM) ± SD (HEK293)aEntry 
CYP1A1 CYP1B1 CYP1A1 CYP1B1
Pongamol 2.4  ± 0.5 3.9 ± 0.7 4.6 ± 0.5 5.6 ± 0.5
P5a 6.8 ± 0.4 6.2 ± 1.1 8.6 ± 0.4 25.5 ± 2.6
P5b 0.28 ± 0.07 >20 0.49 ± 0.22 5.7 ± 1.1
ANFb 0.05 ± 0.02 0.04 ± 0.02 >10 >10
aAll values represent mean and standard deviations (± SD) from three independent experiments. bANF (-
naphthoflavone) was used as a positive control in this experiment.
The results in Table 3 clearly indicate that although ANF is a potent inhibitor of CYP1A1 and 
CYP1B1, as has been reported before, it does not inhibit CYP1A1 and CYP1B1 enzymes 
expressed within live HEK293 cells, grown in suspension. One reason for this could be that ANF 
is highly insoluble20, 48, 49, 55 and that it precipitates in cell culture media.
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2.3. Furanochalcones Pongapin and Lanceolatin B are Selective Inhibitors of CYP1 Sub-
family of Enzymes. To understand the selectivity profile, the two best compounds pongapin and 
lanceolatin B were tested against a panel of 12 human CYP450 enzymes viz. CYP1A1, 
CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, 
CYP2E1, and CYP3A4 using Sacchrosomes™.  Both pongapin and lanceolatin B manifested the 
most potent inhibitory activity against CYP1A1 enzyme (with IC50 values, 71 and 76 nM, 
respectively) with lesser inhibitory activity against CYP1B1 and CYP1A2. Amongst the two 
compounds, pongapin showed excellent selectivity within CYP1 sub-family of enzymes (13 and 
35-fold selectivity towards CYP1A1 over CYP1B1 and CYP1A2, respectively) (Table 4). 
Interestingly, both these compounds do not inhibit CYP2 and CYP3 sub-family of enzymes (IC50 
≥ 20 µM), indicating their selective inhibition of CYP1 sub-family of enzymes.
Table 4. Profiling of pongapin and lanceolatin B against a panel of CYP1, CYP2 and CYP3 sub-family 
enzymes, using Sacchrosomes™.
IC50 (µM) ± SD (SacchrosomesTM)aCYP
Pongapin Lanceolatin B
CYP1A1 0.071 ± 0.008 0.076 ± 0.008
CYP1A2 2.5 ± 0.21 0.187 ± 0.12
CYP1B1 0.95 ± 0.12 0.29 ± 0.07
CYP2A6 >20 >20
CYP2B6 >20 >20
CYP2C8 >20 >20
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CYP2C9 >20 >20
CYP2C18 >20 >20
CYP2C19 >20 >20
CYP2D6 >20 >20
CYP2E1 >20 >20
CYP3A4 >20 >20
aAll values represent mean and standard deviations (± SD) from three independent experiments.
2.4. The Potent CYP1A1 Inhibitors Identified Protect Human CYP1A1-overexpressing 
HEK293 Cells from B[a]P-mediated Toxicity. The aryl hydrocarbon hydroxylase (CYP1A1) is 
involved in the metabolic activation of aromatic hydrocarbons. It catalyzes the oxidation of 
B[a]P to form B[a]P-7,8-epoxide which further oxidizes to B[a]P-7,8-dihydrodiol. With the help 
of an epoxide hydrolase, B[a]P-7,8-dihydrodiol is finally converted to B[a]P-7,8-dihydrodiol-
9,10-epoxide which is a carcinogen. In this study, we took recombinant HEK293 cells that 
harbor a plasmid that encodes the human CYP1A1 gene and cells which contained a plasmid 
without the CYP1A1 gene (i.e. an empty plasmid).20, 48, 49 B[a]P causes toxicity (i.e. inhibits cell 
growth) in both cell types but with different EC50 values (i.e. the half maximal inhibitory 
concentrations relating to block in cell growth). The EC50 for cell growth inhibition by B[a]P in 
HEK293 cells, transfected with the empty plasmid, was found to be 14 ± 1.2 µM; whereas the 
EC50 value of B[a]P is ~10-fold lower in cells (i.e. HEK293::pcDNA3.1/CYP1A1) transfected 
with the plasmid encoding the human CYP1 gene cells (EC50 = 1.4 ± 0.4). This is because the 
CYP1A1-mediated metabolic activation of B[a]P produces a toxic metabolite and therefore there 
is more cellular toxicity that translates to more efficient block in cell growth.
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The methanolic extract (ME), three natural products pongamol, pongapin, lanceolatin B and 
one semisynthetic derivative P5b were tested for their ability to rescue human HEK293 cells 
from B[a]P toxicity. The ME completely rescued human cells from CYP1A1-mediated B[a]P 
toxicity at 3 x IC50 concentration, restoring the EC50 value of B[a]P. The furanoflavones, 
pongapin and lanceolatin B at 0.06 µM concentration (i.e. at 3 x IC50), completely protected 
human cells from B[a]P toxicity, restoring EC50 value of B[a]P to 14.8 and 14.4 µM, 
respectively. The furanochalcone, pongamol and its derivative P5b (at 3 x IC50 concentrations) 
also rescued human cells from B[a]P toxicity but could restore the EC50 value of B[a]P only to 
10.2 and 12.8 µM, respectively (which is 73 and 91% rescue). Results are shown in Figure 3.
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Figure 3. Protection of HEK293 cells from B[a]P toxicity. EC50 values of B[a]P after treatment of 
CYP1A1-overexpressing adherent HEK293 cells with B[a]P and a CYP1A1 inhibitor are plotted. A range 
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of concentrations of B[a]P (0.05 µM – 100 µM) were used, in the presence of 3 x IC50 values of the 
compounds or at 3 x IC50 value of ME (as determined in the human cell assay where cells, grown in 
suspension, expressed CYP1A1). Adherent HEK293 cells were transfected with pcDNA3.1/hCYP1A1 
(plasmid encoding the human CYP1A1 gene). ANF (alpha-naphthoflavone) was used as a positive control 
in this experiment. All values, presented in µM concentrations, represent the mean and standard 
deviations of three independent experiments (statistical analysis. ***P < 0.001; ** P < 0.005; * P < 0.01; 
ns: not significant; P > 0.01).
2.5. Pongapin and Lanceolatin B Block Cell Growth in MCF7-1A1 Cells (i.e. MCF-7 
Breast Cancer Cells That Overexpress CYP1A1) at G0-G1 Phase of the Cell Cycle and 
Repress Cyclin D1 Levels. It has been reported that siRNA-mediated knockdown of CYP1A1 
inhibits cell proliferation of MCF-7 breast cancer cells blocking cell growth at the G0-G1 phase 
of the cell cycle.28 However, it was also noted that ANF, a published CYP1A1 inhibitor,29 does 
not affect MCF-7 cell proliferation. We have reported earlier that ANF is unable to inhibit 
potently CYP1A1 enzyme expressed within HEK293 cells;19, 21, 30 also Table 3 of this paper). We 
have now confirmed that ANF (50 µM concentration) has no effect on the proliferation of 
MCF7-1A1 cells (compare Figures 4B and 4C), which stably overexpress CYP1A1 from a 
plasmid encoding the human CYP1A1 gene (Figure 4A). ANF’s EC50 value for inhibition of 
MCF7-1A1 cell proliferation was determined to be >20 µM. Nevertheless, the methanolic extract 
(EC50 for inhibition of proliferation of MCF7-1A1, 3.8 ± 0.4 µg/mL) from the seeds of P. 
pinnata, and the plant’s secondary metabolites pongapin (EC50 for inhibition of MCF7-1A1 
proliferation, 0.6 ± 0.15 µM), lanceolatin B (EC50 for inhibition of MCF7-1A1 proliferation, 0.7 
± 0.12 µM) do block MCF7-1A1 cells at G0-G1 (compare Figures 4D, 4E, 4F with 4A) and 
repress cyclin D1 levels (Figure 4F), when cells were treated with 2x EC50 concentration of 
extract or metabolites. Cyclin dependent kinase-4 (Cdk4), which acts at G0-G1, is activated by 
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cyclin D1. With greatly diminished levels of cyclin D1, Cdk4 is unable to be appropriately 
active. Hence, because of Cdk4 inactivation, cells probably cannot progress from the G0-G1 
phase and, thus, cannot proliferate.56, 57
G1: S ratio = 2.7
G0/G1 = 54.3%
S = 20.1%
G2/M = 22.6%
Control Methanolic ExtractANF Pongapin Lanceolatin B
G1: S ratio = 12.5
G0/G1 = 83.8%
S = 6.7%
G2/M = 8.3%
G1: S ratio = 2.3
G0/G1 = 55.4%
S = 24.1%
G2/M = 20.5%
G1: S ratio = 7.1
G0/G1 = 77.2%
S = 10.7%
G2/M = 11.6%
(B) (C) (D) (E) (F)
G1: S ratio = 11.3
G0/G1 = 81%
S = 7.1%
G2/M = 9.2%
1         2        3          4         5(G)(A) 1       2       3
CYP1A1
-tubulin
cyclin D1
-tubulin
No compound          ME                    Pongapin Lanceolatin B
(H)
C ntrol  E ongapin Lanceolatin B
Figure 4.(A-F). Effect of CYP1A1 inhibitors, identified in P. pinnata seeds, on the cell division cycle of 
MCF7-1A1 cells that overexpress CYP1A1. (A): Western blot of MCF7-1A1 cells overexpressing 
CYP1A1. Lane 1, MCF-7 cells transfected with the plasmid pcDNA3.1/CYP1A1, lane 2, 2 picomoles of 
CYP1A1-Sacchrosomes™, lane 3, MCF-7 cells transfected with an empty plasmid. (B) to (F): cell cycle 
analyses (i.e. FACS analyses) of asynchronous MCF7-1A1 cells after treatment, for 24 h, with 2x EC50 
concentration of compounds [(C), (E) and (F)]and methanolic extract [(D)], or in the absence of any 
compound or extract [(B)]. (G): Western blot of MCF7-1A1 cells, after treatment with compounds/seed-
extract for 24 h, to assess cyclin D1 levels within cells. Lane 1, Control, untreated asynchronous MCF7-
1A cells; asynchronous MCF7-1A cells treated with ANF (lane 2), methanolic extract (lane 3), pongapin 
(lane 4) and lanceolatin B (lane 5). Beta-tubulin was used as a loading control in both Western blots. The 
CYP1A1, cyclin D1 and -tubulin-specific antibodies, used for monitoring protein expression, were from 
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ProteinTech (#13241-1-A; CYP1A1), Santa Cruz Biotechnology (#sc-718) and Abcam (#ab6046; -
tubulin).  (H). MCF7-1A1 cells showing induction of β-galactosidase, a senescence-associated marker, 
upon treatment with 2x EC50 concentration of P. pinnata seed-extract (ME - methanolic extract), 
pongapin and lanceolatin B. Untreated and treated cells were stained for β-galactosidase activity after 96 
h. The stained cells were observed under a phase-contrast microscope (Olympus CKX41) and the 
percentage of cells expressing β-galactosidase was determined. The blue-stained cells indicate β-
galactosidase activity, a marker for senescence.
2.6. Pongapin and Lanceolatin B Induce Senescence in MCF7-1A1 Cells. Cellular 
inhibition of Cdk4 enzyme, in cancer cells, may induce apoptosis and/or senescence which is a 
state analogous to terminal differentiation.58-60 Since our cell cycle analyses (Figures 4B to D) 
did not show a sub-G1 peak, which is normally indicative of apoptosis, when MCF7-1A1 cells 
were treated with the seed-extract of P. pinnata, and its secondary metabolites pongapin and 
lanceolatin B, we tested if MCF7-1A1 cells underwent senescence. Senescence is reflected by 
induction of senescence-associated markers such as neutral β-galactosidase. Interestingly, it was 
found that the P. pinnata seed-extract, pongapin and lanceolatin B do induce β-galactosidase in 
MCF7-1A1 cells (Figure 4H). Approximately 60-70% cells were positive for β-galactosidase 
activity out of which more than 20% cells were strongly positive (cells staining dark blue). The 
control MCF7-1A1 cultures showed less than 10% cells positive for β-galactosidase and were 
weakly stained (cells stained light blue).
2.7. Molecular Modelling of Pongapin, Lanceolatin B and a Pyrazole Derivative P5b 
with CYP1A1. The X-ray crystal structure of human CYP1A1 (PDB ID: 4I8V), published in 
2013 by Walsh and co-workers 11, was used for this study. Docking of the three inhibitors 
pongapin, lanceolatin B and a pyrazole derivative P5b was carried out using GLIDE module of 
Schrodinger molecular modeling suite. The docking protocol was validated by re-docking ANF29  
  
19
in the CYP1A1 active site (Figure 5A). The interactions of pongapin, lanceolatin B and pyrazole 
derivative P5b, with the active site residues of CYP1A1, are shown in Figures 5B, 5C and 5D, 
respectively. Pongapin showed four important H-bonding interactions with Thr 497, Thr 321, 
Asn 222 and Asp 320 amino acid residues, along with two - interactions with Phe 224 and Phe 
123 residues. Unlike pongapin, lanceolatin B oriented in the active site of CYP1A1, with furan 
ring closer to the heme. The carbonyl group of lanceolatin B showed H-bonding interactions 
with Asn 222 and Thr 497 residues. The chroman and phenyl ring of lanceolatin B showed - 
interactions with Phe 258 and Phe 224 residues. Additionally, the furan ring also displayed - 
interaction with Phe 123 amino acid. Interestingly, the pyrazole derivative P5b displayed several 
additional interactions along with other shared interactions of the three inhibitors. Like 
lanceolatin B, the furan ring of P5b oriented towards the heme. The furan oxygen showed H-
bonding with Ile 386. Other H-bonding interactions of P5b include the interaction between 1′-N 
of pyrazole with Thr 321 and Asp 320, and interaction of CN with Thr 497 residue. Apart from 
these interactions, three hydrophobic - interactions were observed with Phe 224, Phe 258 and 
Phe 319 residues. Docking studies indicated that these identified CYP1A1 inhibitors display 
strong binding and interactions at the active site of CYP1A1 enzyme.
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Figure 5. Molecular modeling of ANF, pongapin, lanceolatin B and the pyrazole derivative P5b with 
CYP1A1 (PDB: 4I8V). (A) Overlay of ANF on co-crystal crystal structure (red) and docked ANF 
(green). (B) Interactions of pongapin with CYP1A1. (C) Interactions of lanceolatin B with CYP1A1. (D) 
Interactions of the pyrazole derivative P5b with CYP1A1.
3. CONCLUSIONS
In summary, we have identified that the methanolic extract of P. pinnata seeds displays strong 
inhibition of CYP1 sub-family of enzymes. The two furanoflavone secondary metabolites 
isolated from P. pinnata seeds, pongapin and lanceolatin B, were identified as highly potent and 
selective inhibitors of CYP1A1 (both having CYP1A1 IC50 values of 20 nM in human cells) with 
little effect on CYP2 and 3 sub-family of enzymes (IC50, >20 µM). The seed-extract, pongapin 
and lanceolatin B, protect human cells, expressing CYP1A1, from the toxicity of the 
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procarcinogen B[a]P. We have confirmed earlier findings 28 that the CYP1A1 inhibitor ANF has 
no effect on the cell division cycle. Surprisingly however, pongapin and lanceolatin B block 
breast cancer MCF-7 cells, that overexpress CYP1A1, at G0-G1 phase of the cell division cycle, 
with perceptible reduction in cyclin D1 levels. It appears that this early arrest of the cell cycle 
causes cellular senescence, a yet unreported facet of CYP1A1 inhibition. Thus, the leads 
identified, herein, have potential for further investigation as potential cancer chemopreventive 
agents.
4. EXPERIMENTAL SECTION
4.1. General. All chemicals were obtained from Sigma-Aldrich Company and used as 
received. 1H, 13C and DEPT NMR spectra were recorded on Bruker-Avance DPX FT-NMR 500 
and 400 MHz instruments. Chemical data for protons are reported in parts per million (ppm) 
downfield from tetramethylsilane and are referenced to the residual proton in the NMR solvent 
(CDCl3, 7.26 ppm). Carbon nuclear magnetic resonance spectra (13C NMR) were recorded at 125 
MHz or 100 MHz: chemical data for carbons are reported in parts per million (ppm, δ scale) 
downfield from tetramethylsilane and are referenced to the carbon resonance of the solvents 
(CDCl3: 77.36 ppm). ESI-MS and HRMS spectra were recorded on Agilent 1100 LC-Q-TOF and 
HRMS-6540-UHD machines. IR spectra were recorded on Perkin-Elmer IR spectrophotometer. 
Melting points were recorded on digital melting point apparatus. The HPLC analysis was carried 
out on Shimdzu HPLC system using Chromolith C-18e column (Merck, 4.6 X 2.5 mm) and PDA 
detector. The authentic plant material Pongamia pinnata(L.) Pierre was provided by the 
biodiversity and applied botany division of Indian Institute of Integrative Medicine (CSIR), 
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Jammu, from the plain area of the Jammu region of India. A specimen sample (accession 
number: 22898) was preserved in Janaki Ammal Herbarium at the IIIM (CSIR), Jammu, India
4.2. Extraction and Isolation. Three extracts viz. methanol, hydroalcoholic and chloroform 
were prepared for activity profiling. For phytochemical investigation, the dried and powdered 
seeds (2.5 kg) were extracted by cold percolation, with methanol (3 × 2 L), and the combined 
filtrate was concentrated to afford 1000 g of extract. This extract was suspended in water and 
sequentially fractionated with different solvents including hexane, ethyl acetate, chloroform, and 
n-butanol yielding 200, 400, 90 and 120 g extracts, respectively. The ethyl acetate fraction (400 
g) was subjected to column chromatography using step-gradient system of hexane and ethyl 
acetate in the range of 3 to 50%, which yielded ten major fractions. The 9th fraction produced 
karanjin (200 mg), which was obtained in pure form by crystallization in methanol. The 3rd and 
4th fraction contained an oily compound, which was subjected to crystallization in methanol to 
obtain pongamol (350 mg). The 5th and 6th fraction on crystallization in methanol gave 
ovalitenone (50 mg) as a white powder. The 10th fraction gave the white fluffy compound pongol 
(200 mg) after silica gel column chromatography. The 7th fraction produced the yellow 
crystalline compound pongapin (10 mg) which was subjected to crystallization. Isolated 
compounds karanjin,20, 61 pongamol,51, 53, 54 ovalitenone,51, 62 pongol63 and pongapin64 were 
characterized by comparison of their spectral data with literature values (Section S2, supporting 
information).
4.3. Synthesis of Lanceolatin B and Pongaglabrone 51. To the solution of pongamol or 
ovalitenone (100 mg, 1 equiv.) in DMF was added K2CO3 (2 equiv.) and the reaction mixture 
was stirred at 60 °C for 12 h. After completion of the reaction, the reaction mixture was 
partitioned between water and dichloromethane. The organic layer was collected and evaporated 
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in vacuo and the crude product was purified using silica gel column chromatography to obtain 
lanceolatin B and pongaglabrone, respectively. Both these compounds were characterized by 
comparison of their spectral data with literature values.51
4.4. Synthesis of Oxazole Derivatives P1a and P1b. Pongamol (100 mg, 1 mmol) was 
dissolved in acetic acid (3 mL) followed by addition of hydroxylamine hydrochloride (28 mg, 
1.2 equiv) at 70 οC for 4 h under inert atmosphere. After completion of the reaction, it was 
concentrated under reduced pressure. The reaction mixture was diluted with chloroform and 
water was added to the resultant mixture leading to formation of a white precipitate in the 
aqueous layer. The organic layer was decanted off and the remaining solid residue was washed 
two times with chloroform. The combined chloroform layer was evaporated under reduced 
pressure and the residue obtained was purified by silica gel (#100-200) column chromatography 
using hexane-ethyl acetate as an eluent to yield oxazoles P1a and P1b in 64% yield (combined 
yield of isomers).
4.4.1.  3-(4-Methoxybenzofuran-5-yl)-5-phenylisoxazole (P1a). Viscous brown liquid [31 mg, 
32% from pongamol]; HPLC tR 5.2 min (100% purity); IR (CHCl3) max 3385, 3172, 3001, 2989, 
2919, 2850, 1883, 1730, 1611, 1590, 1572, 1484, 1456, 1416, 1394 cm-1; 1H NMR (400 MHz, 
CDCl3)  (ppm) 7.88-7.86 (m, 3H, CH),  7.63 (d, J = 2.2 Hz, 1H, CH-2), 7.51-7.45 (m, 3H, CH), 
7.33 (d, J = 8.6 Hz, 1H, CH-7), 7.06 (s, 1H, CH-4'), 7.01 (d, J = 4.0 Hz, 1H, CH-3), 4.10 (s, 3H, 
OMe); 13C NMR (100 MHz, CDCl3)  (ppm) 168.4 (C-5'), 159.8 (C-3'), 156.7 (C-7a), 150.8 (C-
4), 143.4 (C-2), 128.9 (C-4''), 127.9 (C-3'', C-5''), 126.8 (C-2'',C-6''), 124.7 (C-6), 118.2 (C-3a), 
113.6 (C-5), 106.0 (C-7), 103.9 (C-3), 99.6 (C-4'), 59.6 (OMe); HR-ESIMS m/z 292.0964 
[M+H]+ (calcd  for C18H14NO3, 292.0968).
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4.4.2.  5-(4-Methoxybenzofuran-5-yl)-3-phenylisoxazole (P1b). brown crystalline solid [32 
mg, 32% from pongamol]; HPLC tR 5.4 min (100% purity); mp 107-108 οC;  IR (CHCl3) max 
3417, 3018, 2918, 2850, 2099, 1736, 1643, 1605, 1571, 1484, 1467, 1417, 1401, 1352 cm-1; 1H 
NMR (400 MHz,  CDCl3)  (ppm) 7.96 (d, J = 8.7 Hz, 1H, CH), 7.91 (dd, J = 7.7, 1.5 Hz, 2H, 
CH),  7.63 (d, J = 2.1 Hz, 1H, CH-2), 7.51-7.46 (m, 3H, CH), 7.31 (d, J = 8.0 Hz, 1H, CH-7), 
7.08 (s, 1H, CH-4'), 7.05 (d, J = 1.4 Hz, 1H, CH-3), 4.23 (s, 3H, OMe); 13C NMR (100 MHz, 
CDCl3)  (ppm) 167.1 (C-5'), 163.1 (C-3'), 157.9 (C-7a), 151.1 (C-4), 144.7 (C-2), 129.9 (C-3'', 
C-5''), 129.7 (C-2'', C-6''), 129.0 (C-1''), 127.0 (C-4'') 124.2 (C-6), 118.4 (C-3a), 113.0 (C-5), 
106.9 (C-7), 105.4 (C-3), 100.4 (C-4'), 60.1 (OMe); HR-ESIMS m/z 292.0953 [M+H]+ (calcd  for  
C18H14 NO3,292.0968).
4.5. Synthesis of Pyrazole Derivatives P2a-P7a and P1b-P7b. Pongamol (100 mg, 1 mmol) 
was dissolved in acetic acid (3 mL) followed by addition of substituted phenylhydrazines (1.2 
equiv) at 70 οC for 4 h under inert atmosphere. After completion of the reaction, it was 
concentrated under reduced pressure. The reaction mixture was diluted with chloroform and 
water was added to the resultant mixture leading to formation of a white precipitate in the 
aqueous layer. The organic layer was decanted off and the remaining solid residue was washed 
two times with chloroform. The combined chloroform layer was evaporated under reduced 
pressure and the residue obtained was purified by silica gel (#100-200) column chromatography 
using hexane-ethyl acetate as an eluent to yield pyrazoles as a pair of regioisomers P2a-P7a and 
P1b-P7b in52-73% yield (combined yield of isomers). The mixture of regioisomers were 
separated using semi-preparative HPLC.
4.5.1. 1-(4-Bromophenyl)-5-(4-methoxybenzofuran-5-yl)-3-phenyl-1H-pyrazole (P2a). white 
viscous liquid [52 mg, 34% from pongamol]; HPLC tR 7.7 min (100% purity); IR (CHCl3) 
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max3584, 3362, 3014, 2921, 2851, 1890, 1731, 1591, 1555, 1537, 1493, 1471, 1461, 1447 cm-1; 
1H NMR (400 MHz, CDCl3)  (ppm) 7.93 (d, J = 7.1 Hz, 2H, Ar), 7.60 (d, J = 2.2 Hz, 1H, 
OCH=CH), 7.45-7.33 (m, 5H, ArH), 7.26-7.24 (m, 4H, CH), 6.90 (d, J = 2.1 Hz, 1H, OCH=CH), 
6.78 (s, 1H, CH-4'), 3.68 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3) (ppm) 157.7 (C-3'), 152.1 
(C-7a), 151.0 (C-4), 144.6 (OCH=CH), 141.7 (C-5'), 140.1 (C-1''), 133.2 (C-1), 132.0 (C-3'', C-
5''), 128.9 (Ar-3, Ar-5), 128.2 (Ar-4), 127.4 (Ar-2, Ar-6), 126.0 (C-4''), 125.2 (C-2'', C-6''), 120.3 
(C-6), 118.4 (C-3a), 115.3 (C-5), 106.9 (OCH=CH), 106.3 (CH-4'), 106.4 (CH-7), 59.2 (OMe); 
HR-ESIMS m/z 445.0539 [M+H]+ (calcd  for  C24H18BrN2O2, 445.0546).
4.5.2. 2-(4-Bromophenyl)-5-(4-methoxybenzofuran-5-yl)-3-phenyl-2H-pyrazole (P2b). White 
powder [50 mg, 33% from pongamol];  HPLC tR 8.7 min (100% purity); mp 134-136 οC;  IR 
(CHCl3): max 3386, 2918, 2850, 1737, 1589, 1548, 1491, 1420, 1361, 1337, 1257, 1218, 1180 
cm-1; 1H NMR (400 MHz, CDCl3)  (ppm) 8.01 (d, J = 8.6 Hz, 1H, CH), 7.60 (d, J = 2.2 Hz, 1H, 
OCH=CH), 7.47-7.46 (d, J = 8.7 Hz, 2H, CH), 7.36 (m, 3H, CH), 7.31 (m, 5H, CH), 7.07 (s, 1H, 
CH-4') 6.99 (d, J = 1.4 Hz, 1H, OCH=CH), 4.10 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3):  
(ppm) 156.7 (C-7a), 151.2 (C-5'), 149.6 (C-4), 144.2 (OCH=CH), 143.6 (C-3´), 139.2 (C-1''), 
132.0 (C-3'', C-5''), 130.2 (C-1), 128.8 (Ar-3, Ar-5), 128.6 (Ar-4), 128.4 (Ar-2, Ar-6), 126.5 (C-
4''), 125.3 (C-2'', C-6''), 120.7 (C-6), 119.5 (C-3a), 118.4 (C-5), 109.1 (OCH=CH), 106.9 (CH-
4'), 104.9 (CH-7), 60.5 (OMe); HR-ESIMS m/z 445.0523 [M+H]+ (calcd  for  C24H18 BrN2O2, 
445.0546).
4.5.3. 5-(4-Methoxybenzofuran-5-yl)-2-(perfluorophenyl)-3-phenyl-1H-pyrazole (P3a). 
Brown sticky liquid [48 mg, 31% from pongamol];  HPLC tR 6.3 min (100% purity); IR (CHCl3) 
max 3584, 3385, 2918, 2850, 1737, 1614, 1532, 1515, 1470, 1422 cm-1; 1H NMR (400 MHz,  
CDCl3)  (ppm) 7.90 (d, J = 7.2 Hz, 2H, CH), 7.60 (d, J = 2.2 Hz, 1H, OCH=CH), 7.45-7.43 (m, 
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3H, CH), 7.26 (m, 2H, Ar-H), 6.89 (d, 1H, J = 2.2 Hz, OCH=CH), 6.85 (s, 1H, CH-4'), 3.85 (s, 
3H, OMe); 19F  NMR (376.5 Hz, CDCl3)  (ppm) -144.90 to -144.94 (d, 2F), -152.98 (s, 1F), -
161.74 to -161.75 (d, 2F);  13C NMR (100 MHz, CDCl3)  (ppm) 161.7 (C-2'', C-6'') , 157.4 (C-
3'), 154.0 (C-7a), 152.9 (C-4''), 150.8 (C-4), 144.9 (C-3'', C-5''), 144.8 (C-5´), 144.5 (OCH=CH), 
132.2 (Ar-1), 128.6 (Ar-3, Ar-5), 128.3 (Ar-4), 126.8 (Ar-2, Ar-6), 125.8 (C-6), 118.3 (C-3a), 
118.1 (C-5), 113.6 (C-1''), 106.4 (C-4´), 106.4 (OCH=CH), 104.8 (C-7), 59.8 (OMe); HR-
ESIMS m/z 457.0961 [M+H]+ (calcd  for C24H14F5N2O2, 457.0970).
4.5.4. 5-(4-Methoxybenzofuran-5-yl)-2-(perfluorophenyl)-3-phenyl-2H-pyrazole (P3b). 
White crystalline solid [45 mg, 29% from pongamol]; HPLC tR 6.6 min (100% purity); mp 157-
159 οC; IR (CHCl3) max 3427, 2919, 2851, 2088, 1642, 1529, 1516, 1465, 1340, 1215, 1080 cm-
1; 1H NMR (400 MHz, CDCl3)  (ppm) 7.93 (d, J = 8.7 Hz, 1H, CH), 7.60 (d, J = 2.2 Hz, 
1H,OCH=CH), 7.38 (m, 3H, CH), 7.31 (m, 3H, CH), 7.13 (s, 1H, CH-4´), 7.00 (d, J = 1.4 Hz, 
1H, OCH=CH), 4.11 (s, 3H, OMe);  19F NMR (376.5 Hz, CDCl3)  (ppm) -144.45 to -144.50 (d, 
2F), -152.05 (s, 1F), -160.98 to -161.00 (d, 2F); 13C NMR (100 MHz, CDCl3)  (ppm) 161.0 (2'', 
C-6''), 157.0 (C-7a), 152.0 (C-4''), 152.0 (C-4), 151.5 (C-5'), 144.4 (C-3'', C-5''), 147.1 (C-3´), 
144.2 (OCH=CH), 129.3 (Ar-3, Ar-5), 129.1 (Ar-1), 128.8 (Ar-4), 127.7 (Ar-2, Ar-6), 125.4 (C-
6), 119.5 (C-3a), 118.9 (C-5), 117.8 (C-1´´), 108.0 (C-4´), 106.9 (C-7), 104.9 (OCH=CH), 60.5 
(OMe); HR-ESIMS m/z 457.0959 [M+H]+ (calcd  for  C24H14F5N2O2, 457.0970).
4.5.5. 5-(4-Methoxybenzofuran-5-yl)-1-(2-nitrophenyl)-3-phenyl-1H-pyrazole (P4a). yellow 
viscous liquid [48 mg, 34% from pongamol]; HPLC tR 5.7 min (100% purity); IR (CHCl3) max 
3584, 3402, 3019, 2919, 1736, 1615, 1533, 1469, 1348 cm-1; 1H NMR (400 MHz,  CDCl3)  
(ppm) 8.38 (t, J = 2.0 Hz, 1H, CH), 8.07 (dd, J = 8.2, 1.2 Hz, 1H, CH), 7.95 (d, J = 7.2 Hz, 2H, 
CH), 7.63 (d, J = 2.2 Hz, 1H, OCH=CH), 7.61 (d, J = 8.2 Hz, 1H, CH), 7.45-7.37 (m, 4H, CH), 
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7.30 (m, 2H, CH ), 6.88 (d, J = 2.2 Hz, 1H, OCH=CH ), 6.82 (s, 1H, CH-4´), 3.71 (s, 3H, OMe); 
13C NMR (100 MHz, CDCl3)  (ppm) 157.7 (C-7a), 152.6 (C-4), 150.7 (C-3´), 148.3 (C-5´), 
144.6 (OCH=CH), 141.9 (C-2´´), 141.8 (C-1´´), 132.6 (Ar-1), 129.3 (C-5´´), 128.7 (Ar-3, Ar-5), 
128.6  (Ar-4), 128.3 (C-3´´), 127.0 (C-4´´), 125.8 (Ar-2, Ar-6 ), 121.1 (C-6), 118.4 (C-6´´), 118.2 
(C-3a), 114.6 (C-5), 107.4 (C-4´), 106.4 (C-7), 105.0 (OCH=CH), 59.4 (OMe); HR-ESIMS m/z 
412.1285 [M+H]+ (calcd  for  C24H18N3O4, 412.1291).
4.5.6. 5-(4-Methoxybenzofuran-5-yl)-2-(2-nitrophenyl)-3-phenyl-2H-pyrazole (P4b). yellow 
sticky solid [54 mg, 39% from pongamol];  HPLC tR 6.2 min (100% purity); IR (CHCl3) max 
3584, 2918, 2850, 1737, 1613, 1590, 1531, 1502, 1475, 1432, 1413, 1339, 1351, 1256, 1180 cm-
1; 1H NMR (400 MHz,  CDCl3)  (ppm) 8.36 (t, J = 2.0 Hz, 1H, CH), 8.13 (dd, J = 8.2, 1.2 Hz, 
1H, CH-3´´), 8.04 (d, J = 8.6 Hz, 1H, CH), 7.66 (d, J = 8.0 Hz, 1H, CH), 7.61 (d, J = 2.2 Hz, 1H, 
OCH=CH), 7.48 (t, J = 8.1 Hz, 1H, CH), 7.36-7.32 (m, 6H, CH), 7.11 (s, 1H, CH-4'), 7.00 (d, J 
= 1.4 Hz, 1H, OCH=CH), 4.12 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3)  (ppm) 156.9 (C-6), 
151.4 (C-4), 150.4 (C-5´), 148.4 (C-3´), 144.3 (OCH=CH), 143.9 (C-2´´) 141.1 (C-1´´), 130.2 ( 
C-5´´), 130.2 (Ar-1), 129.5 (C-4´´), 128.9 (Ar-3, Ar-5), 128.7 (Ar-4), 128.8  (Ar-2, Ar-6),  125.3 
(C-3´´), 121.4 (C-6), 119.6 (C-6´´), 119.4 (C-3a), 117.9 (C-5), 109.9 (C-4´), 107.0 (C-7), 104.9 
(OCH=CH), 60.5 (OMe); HR-ESIMS m/z 412.1287 [M+H]+ (calcd  for C24H18N3O4,  412.1291).
4.5.7. 4-(5-(4-Methoxybenzofuran-5-yl)-3-phenyl-1H-pyrazol-1-yl)benzonitrile (P5a). 
white powder [44 mg, 33% from pongamol]; HPLC tR 4.2 min (100% purity); mp 140-146 οC;  
IR (CHCl3): max 3584, 3420, 3040, 2900, 2840, 2200, 1600, 1510, 1474, 1410, 1364, 1217, 
1064 cm-1; 1H NMR (400 MHz,  CDCl3)  (ppm) 7.93 (d, J = 7.2 Hz, 2H, CH), 7.62 (d, J = 2.2 
Hz, 1H, OCH=CH), 7.56 (d, J = 8.7 Hz, 2H, CH), 7.49-7.43 (m, 4H, CH), 7.38 (d, J = 7.3 Hz, 
1H, CH),  7.30 (s, 2H, CH), 6.90 (d, J = 2.2 Hz, 1H, OCH=CH), 6.81 (s, 1H, CH- 4´), 3.67 (s, 
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3H, OMe); 13C NMR (100 MHz, CDCl3)  (ppm) 156.9 (C-7a), 151.4 (C-4), 150.6 (C-3´), 144.2 
(OCH=CH), 143.9 (C-5´), 143.5 (C-1´´), 132.8 (C-3´´), 130.4 (Ar-1), 128.9 (Ar-3, Ar-5), 128.6 
(Ar-4), 128.7 (Ar-2, Ar-6), 125.8 (C-5´´), 125.3 (C-4´´), 124.6 (C-6´´), 123.1 (C-6), 119.4 (C-
3a), 118.4 (C-5), 117.9 (C=N), 110.4 (C-2´´), 110.1 (C-4´), 106.9 (OCH=CH), 104.9 (C-7), 60.4 
(OMe); HR-ESIMS m/z 392.1380 [M+H]+ (calcd  for  C25H18N3O2, 392.1393).
4.5.8. 4-(5-(4-Methoxybenzofuran-5-yl)-3-phenyl-2H-pyrazol-2-yl)benzonitrile (P5b). white 
powder [47 mg, 35% from pongamol]; HPLC tR 4.7 min (100% purity); mp 139-140 οC;  IR 
(CHCl3) max 3584, 3402, 2955, 2918, 2850, 2228, 1737, 1606, 1511, 1465, 1422, 1362, 1339, 
1219 cm-1; 1H NMR (400 MHz,  CDCl3):  (ppm) 8.03 (d, J = 8.6 Hz, 1H, CH), 7.61 (d, J = 1.4 
Hz, 1H, OCH=CH), 7.60 (d, J = 4.0 Hz, 2H, CH), 7.52 (d, J = 8.6 Hz, 2H, CH), 7.40 (dd, J = 
5.0, 1.6 Hz, 3H, CH), 7.32 (m, 3H, CH), 7.09 (s, 1H, CH-4´), 6.99 (d, J = 1.4 Hz, 1H, 
OCH=CH), 4.11 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3)  (ppm) 156.7 (C-7a), 151.0 (C-4), 
149.7 (C-5´), 144.1 (OCH=CH), 143.8 (C-3´), 143.3 (C-1´´), 132.7 (C-3´´), 130.1 (Ar-1), 128.7 
(Ar-3, Ar-5), 128.7 (Ar-2, Ar-6), 128.6 (Ar-4), 125.5 (C-5´´), 125.1 (C-4´´), 124.7 (C-6´´), 123.5 
(C-6), 119.1 (C-3a), 118.1 (C-5), 117.7 (C=N), 110.2 (C-2´´), 110.1 (C-4´), 106.8 (OCH=CH), 
105.8 (C-7), 60.5 (OMe); HR-ESIMS m/z 392.1380 [M+H]+ (calcd for C25H18N3O2,  392.1393).
4.5.9. 1-(2-Chlorophenyl)-5-(4-methoxybenzofuran-5-yl)-3-phenyl-1H-pyrazole (P6a). 
viscous brown liquid [46 mg, 34% from pongamol];  HPLC tR 7.3 min (100% purity); IR 
(CHCl3) max 3382, 3063, 2918, 2850, 1889, 1733, 1594, 1555, 1496, 1470, 1447 cm-1; 1H NMR 
(400 MHz,  CDCl3)  (ppm) 7.93 (d, J = 7.2 Hz, 2H, CH), 7.60 (d, J = 2.2 Hz, 1H, OCH=CH), 
7.45 (t, J = 7.5 Hz, 2H, CH), 7.33 (m, 3H, CH), 7.26 (m, 4H, CH), 6.89 (d, J = 2.2 Hz, 1H, 
OCH=CH), 6.78 (s, 1H, CH-4´),  3.68 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3)  (ppm) 157.5 
(C-7a), 152.0 (C-4), 150.9 (C-3´), 144.4 (OCH=CH), 141.4 (C-5´), 139.5 (C-1´´), 133.1 (Ar-1), 
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132.3 (C-4´´), 128.7 (Ar-3, Ar-5), 128.6 (Ar-4), 128.0 (Ar-2, Ar-6), 127.2 (C-3´´, C-5´´), 125.8 
(C-6), 124.7 (C-2´´, C-6´´), 118.3 (C-3a), 115.2 (C-5), 106.7 (C-4´), 106.1 (C-7), 106.1 
(OCH=CH)), 59.3 (OMe); HR-ESIMS m/z 401.1050 [M+H]+ (calcd  for C24H18ClN2O2, 
401.1051).
4.5.10. 2-(2-Chlorophenyl)-5-(4-methoxybenzofuran-5-yl)-3-phenyl-2H-pyrazole (P6b). 
crystalline solid [42 mg, 31% from pongamol];  HPLC tR 8.2 min (100% purity);  mp 151-153 
οC;  IR (CHCl3) max 3429, 3018, 2919, 2850, 2095, 1732, 1639, 1549, 1495, 1473, 1421, 1362, 
1337, 1217, 1180, 1153, 1093 cm-1; 1H NMR (400 MHz,  CDCl3)  (ppm) 8.02 (d, J = 8.6 Hz, 
1H, CH), 7.60 (d, J = 2.2 Hz, 1H, OCH=CH), 7.36 (m, 3H, CH), 7.32 (m, 7H, CH), 7.07 (s, 1H, 
CH-4´), 6.99 (d, J = 1.4 Hz, 1H, OCH=CH), 4.10 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3)  
(ppm) 156.8 (C-7a), 151.3 (C-4), 149.6 (C-5´), 144.1 (OCH=CH), 143.6 (C-3´), 138.8 (C-1´´), 
132.8 (Ar-1), 130.7 (C-4´´), 129.0 (Ar-3, Ar-5), 128.8 (Ar-4), 128.6 (Ar-2, Ar-6), 128.3 (C-3´´, 
C-5´´), 126.2 (C-6), 125.4 (C-2´´, C-6´´), 119.6 (C-3a), 118.5 (C-5), 109.0 (C-4´), 106.9 (C-7), 
104.1 (OCH=CH), 60.4 (OMe); HR-ESIMS m/z 401.1035 [M+H]+ (calcd  for  C24H18ClN2O2, 
401.1051).
4.5.11. 1-(2,4-Dichlorophenyl)-5-(4-methoxybenzofuran-5-yl)-3-phenyl-1H-pyrazole (P7a). 
crystalline solid [38 mg, 26% from pongamol]; HPLC tR 7.17 min (100% purity); IR (CHCl3) 
max  3584, 3384, 3066, 2918, 2850, 1736, 1592, 1555, 1490, 1470, 1440, 1428, 1348 cm-1; 1H 
NMR (400 MHz, CDCl3)   (ppm) 7.93 (d, J = 7.2 Hz, 2H, CH), 7.57 (d, J = 2.2 Hz, 1H, 
OCH=CH), 7.42 (m, 3H, CH), 7.33 (m, 3H, CH), 7.20 (m, 3H, CH), 6.89 (d, J = 2.1 Hz, 1H, 
OCH=CH ), 6.82 (s, 1H, CH-4´), 3.87 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3)  (ppm) 157.3 
(C-7a), 152.4 (C-4), 150.9 (C-3´), 144.3 (OCH=CH), 143.2 (C-5´), 137.2 (C-1´´), 134.6 (C-2´´), 
133.0 (C-4´´), 132.8 (Ar-1), 130.3 (C-3´´), 130.1 (C-5´´), 128.6 (Ar-3, Ar-5), 128.0 (Ar-4), 127.3 
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(Ar-2, Ar-6),  127.2 (C-6´´), 125.8 (C-6), 118.0 (C-3a), 114.6 (C-5), 105.9 (C-4´), 105.5 (C-7), 
105.1 (OCH=CH), 59.6 (OMe); HR-ESIMS m/z 435.0654 [M+H]+ (calcd  for C24H17Cl2 N2O2, 
435.0661).
4.5.12. 2-(2,4-Dichlorophenyl)-5-(4-methoxybenzofuran-5-yl)-3-phenyl-2H-pyrazole (P7b). 
Crystalline solid [31 mg, 27% from pongamol]; HPLC tR 7.19 min (100% purity); mp 157-159 
οC; IR (CHCl3) max 3443, 2918, 2850, 2095, 1732, 1639, 1549, 1495, 1473, 1421, 1362, 1337, 
1217, 1180, 1153, 1093 cm-1; 1H NMR (400 MHz,  CDCl3)  (ppm) 7.98 (d, J = 8.6 Hz, 1H, 
CH), 7.59 (d, J = 2.2 Hz, 1H, OCH=CH), 7.46 (m, 2H, CH), 7.32 (m, 5H, CH),  7.27 (d, J = 4.0 
Hz, 1H, CH), 7.12 (s, 1H, CH-4´), 6.98 (d, J = 1.4 Hz, 1H, OCH=CH), 4.10 (s, 3H, OMe);  13C 
NMR (100 MHz, CDCl3)  (ppm) 157.4 (C-7a), 152.4 (C-4), 150.9 (C-5´), 144.3 (OCH=CH), 
143.3 (C-3´), 137.2 (C-1´´),  134.7 (C-2´´), 133.1 (C-4´´),  132.8 (Ar-1), 130.3 (C-3´´), 130.1 (C-
5´´), 128.6 (Ar-3, Ar-5), 128.0 (Ar-4), 127.3 (Ar-2, Ar-6),  127.2 (C-6´´), 125.9 (C-6), 118.1 (C-
3a), 114.7 (C-5), 105.9 (C-4´), 105.5 (C-7), 105.1 (OCH=CH)), 59.7 (OMe); HR-ESIMS m/z 
435.0660 [M+H]+ (calcd  for C24H17Cl2 N2O2, 435.0661).
4.6. CYP inhibition. The CYP Screening using SacchrosomesTM and Recombinant Human 
HEK293 Cells was carried out as described earlier.20, 48, 49 Similarly, the protection from B[a]P 
toxicity in CYP1A1-expressing normal adherent human cells was performred using our 
published protocols.19, 20, 48
4.7. Construction of the Stable MCF7-10A Cell Line. After transfection of MCF-7 cells 
(ATCC # HTB-22) with the CYP1A1 gene-bearing pcDNA3.1 plasmid (i.e. 
pcDNA3.1/CYP1A1) 49, using the Amaxa-Nucleofector (following the manufacturer’s 
protocols), and the transfectants were seeded onto a 100-mm tissue culture dish (Corning) 
containing 8 mL of pre-warmed culture medium. After incubation for 2 days, the transfected 
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cells were selected for G418 resistance in medium containing 1 mg/mL G418 (Gibco/BRL Life 
Technologies). After 10-15 days, the surviving single colonies (G418-resistant colonies)were 
picked using cloning rings and transferred to 24-well dishes with further selection in medium 
containing 200 mg/mL G418. The expression of CYP enzymes, in G418-stabilized transfectants, 
were determined using Western blotting, enzyme assay using the fluorogenic substrate, 7-
ethoxyresorufin. The homogeneity of the transfectants was assured by repeated subcloning.
4.8. In Vitro Cell Proliferation Assays and Flow Cytometric Analyses. This assay was 
performed as described earlier 65. Control cells (i.e. in the absence of any compound) and cells 
(i.e. treated with compound) cells were harvested after treatment with trypsin. Cells were fixed in 
chilled (-20 ºC) 70% ethanol for an hour, after washing once with PBS. Fixed cells were 
centrifuged at room temperature. Pellets were re-suspended in PBS, in the presence of DNase-
free ribonuclease (0.5 mg/mL; Sigma-Aldrich # R-5503) before staining with a propidium iodide 
solution (50 μg/mL; Sigma-Aldrich, # P-4170) for an hour (in the dark) at 4 °C. Cell cycle 
analysis was performed on the Beckman Coulter (Epics Altra) fluorescence-activated cell sorter 
(Beckman Coulter UK Ltd). To exclude cell doublets or cell clumps, all events that represent 
single cells were gated. Cytograms of the fluorescence peak of propidium iodide were plotted 
against the integrated fluorescence/linear signal. Data points on a straight line, within a single 
gate, were isolated and the gated data was employed for plotting a histogram that represents a 
complete cell cycle. The total number of events did not exceed 200 events per second. Data 
acquisition was stopped after collection of around 10,000 events.
4.9. Senescence Assay for Expression of β-Galactosidase. Senescent cells can no longer 
replicate because they cannot enter the normal cell cycle and undergo cellular mitosis (i.e. 
senescent cells cannot divide). Senescence, associated with changes in cellular gene expression 
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patterns, results in the expression of β-galactosidase activity which can be assessed by staining 
the cells 66, 67. MCF7-1A1 cells (25,000 cells/well) were seeded in 6-well plates in 2 ml complete 
growth medium. Cells were incubated for 24 h (to allow for stabilization) followed by 96 h of 
treatment with test compound or extract (at IC50 concentrations). After compound/extract 
treatment, the growth medium was removed by aspiration and the cells were washed twice with 1 
ml PBS. 1.5 ml of fixation buffer was added to each well and the plates were incubated at room 
temperature for 10 min. While cells were being fixed, the staining mixture was prepared. Cells 
were washed 3 times with 1 ml PBS and 1 ml of staining mixture was added to each well.  The 
plates were incubated at 37 °C, without CO2, for 48 h. The cells were observed under the 
microscope and the percentage of cells expressing β-galactosidase was determined. 
4.10. Molecular Modeling. The crystal structure of CYP1A1 (PDB ID: 4I8V)11 was retrieved 
from the protein data bank and subjected to protein preparation wizard facility under default 
conditions, implemented in Maestro v9.0 and Impact program v5.5 (Schrodinger, Inc., New 
York, NY, 2009). The prepared protein was further utilized to construct grid file by selecting co-
crystallized ligand as centroid of grid box. For standardization of molecular docking procedure, 
co-crystallized ligand such as ANF (a CYP1A1 inhibitor)29 was extracted from prepared 
enzyme-ligand complex and re-docked to the CYP1A1 binding site. The rest of the chemical 
structures were sketched, minimized and docked using GLIDE XP. The ligand-protein 
complexes were minimized using macromodel. The validation of the docking protocol was done 
by re-docking the co-crystallized ligand from the protein (4I8V). The overlay of co-crystallized 
ligand and re-docked ligand is shown in section S6 of the supporting information. 
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